Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. The company offers
Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. Prime Medicine, Inc. was incorporated in 2019 and is based in Cambridge, Massachusetts. The company trades on NASDAQ exchange. The company headquarter is located in United State. The company was established in the 2019.
| Ticker | PRME |
| Long Name | Prime Medicine, Inc. |
| Short Name | Prime Medicine |